KR102685723B1 - 시트르산의 의약적으로 허용 가능한 염, 혹은 그 수화물 또는 그들의 혼합물을 포함하는 의약 조성물 - Google Patents

시트르산의 의약적으로 허용 가능한 염, 혹은 그 수화물 또는 그들의 혼합물을 포함하는 의약 조성물 Download PDF

Info

Publication number
KR102685723B1
KR102685723B1 KR1020197033580A KR20197033580A KR102685723B1 KR 102685723 B1 KR102685723 B1 KR 102685723B1 KR 1020197033580 A KR1020197033580 A KR 1020197033580A KR 20197033580 A KR20197033580 A KR 20197033580A KR 102685723 B1 KR102685723 B1 KR 102685723B1
Authority
KR
South Korea
Prior art keywords
pharmaceutical composition
concentration
kidney disease
alkalinizing agent
day
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020197033580A
Other languages
English (en)
Korean (ko)
Other versions
KR20190137147A (ko
Inventor
미치아키 아베
세이조 고시바
고이치로 니시오카
가즈히코 가와구치
사토미 야마사키
야스유키 데라나카
Original Assignee
고쿠리츠다이가쿠호진 도호쿠다이가쿠
닛뽕 케미파 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP2017085741A external-priority patent/JP7578234B2/ja
Priority claimed from PCT/JP2017/032931 external-priority patent/WO2018193648A1/ja
Application filed by 고쿠리츠다이가쿠호진 도호쿠다이가쿠, 닛뽕 케미파 가부시키가이샤 filed Critical 고쿠리츠다이가쿠호진 도호쿠다이가쿠
Priority to KR1020247022318A priority Critical patent/KR102773144B1/ko
Publication of KR20190137147A publication Critical patent/KR20190137147A/ko
Application granted granted Critical
Publication of KR102685723B1 publication Critical patent/KR102685723B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/30—Dietetic or nutritional methods, e.g. for losing weight
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
KR1020197033580A 2017-04-18 2018-03-13 시트르산의 의약적으로 허용 가능한 염, 혹은 그 수화물 또는 그들의 혼합물을 포함하는 의약 조성물 Active KR102685723B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020247022318A KR102773144B1 (ko) 2017-04-18 2018-03-13 시트르산의 의약적으로 허용 가능한 염, 혹은 그 수화물 또는 그들의 혼합물을 포함하는 의약 조성물

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
JPJP-P-2017-082423 2017-04-18
JP2017082423 2017-04-18
JP2017085741A JP7578234B2 (ja) 2017-04-18 2017-04-24 アルカリ性化剤による血液浄化
JPJP-P-2017-085741 2017-04-24
JPJP-P-2017-103935 2017-05-25
JP2017103935 2017-05-25
JPPCT/JP2017/032931 2017-09-12
PCT/JP2017/032931 WO2018193648A1 (ja) 2017-04-18 2017-09-12 アルカリ性化剤による血液浄化
PCT/JP2018/009679 WO2018193752A1 (ja) 2017-04-18 2018-03-13 アルカリ性化剤による血液浄化

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020247022318A Division KR102773144B1 (ko) 2017-04-18 2018-03-13 시트르산의 의약적으로 허용 가능한 염, 혹은 그 수화물 또는 그들의 혼합물을 포함하는 의약 조성물

Publications (2)

Publication Number Publication Date
KR20190137147A KR20190137147A (ko) 2019-12-10
KR102685723B1 true KR102685723B1 (ko) 2024-07-16

Family

ID=65033758

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197033580A Active KR102685723B1 (ko) 2017-04-18 2018-03-13 시트르산의 의약적으로 허용 가능한 염, 혹은 그 수화물 또는 그들의 혼합물을 포함하는 의약 조성물

Country Status (8)

Country Link
US (1) US20210121426A1 (https=)
EP (1) EP3616721B1 (https=)
JP (3) JP7219898B2 (https=)
KR (1) KR102685723B1 (https=)
CN (1) CN110799214A (https=)
AU (1) AU2018254884C1 (https=)
CA (1) CA3060154A1 (https=)
TW (1) TWI813560B (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210196747A1 (en) * 2018-05-25 2021-07-01 University Of The Ryukyus Metabolism improving agent
EP3868371A4 (en) 2018-10-17 2022-11-02 Tohoku University Novel pharmaceutical composition
BR112022018917A2 (pt) * 2020-03-26 2022-12-13 Univ Tohoku Agente protetor da função renal
CN114794346A (zh) * 2022-04-25 2022-07-29 武汉汇天诚科技有限公司 一种复合固体饮料的配方

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009032538A1 (en) 2007-08-31 2009-03-12 C.B. Fleet Company, Inc. Method of preventing nephrocalcinosis
JP5197846B2 (ja) 2009-04-30 2013-05-15 紀陽 田仲 腎疾患重篤度を判定する方法又は装置若しくはその作動方法
WO2016153331A1 (es) * 2015-03-20 2016-09-29 Hernández Miramontes Jorge Antonio Mezcla de ácidos carboxilicos para tratar pacientes con insuficiencia renal

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60105619A (ja) * 1983-11-15 1985-06-11 Nippon Chemiphar Co Ltd 尿アルカリ化性食品組成物
JP4087929B2 (ja) * 1997-08-27 2008-05-21 日清ペットフード株式会社 猫慢性腎不全治療用組成物及びその治療方法
JP2004131406A (ja) 2002-10-09 2004-04-30 Sekisui Chem Co Ltd 尿毒症性物質特異的認識ポリマー及び経口吸着剤
EP3066923B1 (en) 2006-01-30 2025-11-05 Panion & BF Biotech Inc. Method of treating chronic kidney disease
JP2007217366A (ja) 2006-02-17 2007-08-30 Kirin Brewery Co Ltd 尿酸値降下用組成物
US20100266712A1 (en) * 2007-05-24 2010-10-21 Austin Health Prevention of Acute Kidney Injury
JP6164719B2 (ja) 2009-10-27 2017-07-19 エイワイファーマ株式会社 白金含有薬剤投与による腎障害の軽減剤
CN105671120B (zh) 2010-07-05 2019-02-19 株式会社明治 具有肠内腐败物质的减少作用的双歧杆菌
JP6490614B2 (ja) * 2015-03-30 2019-03-27 景博 内田 インドキシル硫酸の測定方法
EP3868371A4 (en) * 2018-10-17 2022-11-02 Tohoku University Novel pharmaceutical composition
US20210393562A1 (en) * 2018-10-17 2021-12-23 Nippon Chemiphar Co., Ltd. Therapeutic or prophylactic agent for nocturnal polyuria
US20220202752A1 (en) * 2019-04-28 2022-06-30 Tohoku University Novel pharmaceutical composition

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009032538A1 (en) 2007-08-31 2009-03-12 C.B. Fleet Company, Inc. Method of preventing nephrocalcinosis
JP5197846B2 (ja) 2009-04-30 2013-05-15 紀陽 田仲 腎疾患重篤度を判定する方法又は装置若しくはその作動方法
WO2016153331A1 (es) * 2015-03-20 2016-09-29 Hernández Miramontes Jorge Antonio Mezcla de ácidos carboxilicos para tratar pacientes con insuficiencia renal

Also Published As

Publication number Publication date
JPWO2018193752A1 (ja) 2020-03-05
CN110799214A (zh) 2020-02-14
CA3060154A1 (en) 2018-10-25
JP7756863B2 (ja) 2025-10-21
AU2018254884C1 (en) 2024-04-11
US20210121426A1 (en) 2021-04-29
AU2018254884B2 (en) 2023-12-14
EP3616721C0 (en) 2024-12-04
KR20190137147A (ko) 2019-12-10
TW201838684A (zh) 2018-11-01
EP3616721A4 (en) 2020-12-30
JPWO2018193648A1 (ja) 2020-02-27
AU2018254884A1 (en) 2019-11-07
TWI813560B (zh) 2023-09-01
EP3616721A1 (en) 2020-03-04
JP2023115271A (ja) 2023-08-18
JP7219898B2 (ja) 2023-02-09
EP3616721B1 (en) 2024-12-04

Similar Documents

Publication Publication Date Title
KR102773144B1 (ko) 시트르산의 의약적으로 허용 가능한 염, 혹은 그 수화물 또는 그들의 혼합물을 포함하는 의약 조성물
JP2023115271A (ja) アルカリ性化剤による血液浄化
JP7578243B2 (ja) アルカリ性化剤による血液浄化
WO2020080499A1 (ja) 新規医薬組成物
JP2026063342A (ja) 腎機能保護剤
EP3868370A1 (en) Therapeutic or prophylactic agent for nocturia
EP3868215A1 (en) Agent for improving quality of sleep
KR20220004643A (ko) 신규 의약 조성물
WO2025206119A1 (ja) 治療前の尿アルブミン濃度が特定の範囲である慢性腎臓病の治療のための医薬組成物
HK40079287A (en) Renal function protectant

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

PX0701 Decision of registration after re-examination

St.27 status event code: A-3-4-F10-F13-rex-PX0701

X701 Decision to grant (after re-examination)
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601